Skip to main content

Table 3 Demographics and clinical characteristics of patients with MRSA BSI due to CC5 vs. CC8

From: Everybody nose: molecular and clinical characteristics of nasal colonization during active methicillin-resistant Staphylococcus aureus bloodstream infection

Factor

CC5

N = 28 (%)

CC8

N = 30 (%)

Univariate analysis

OR (95% CI)

p value

Multivariable analysis

OR (95% CI)

p value

Sex

      

Male

20 (71)

16 (53)

2.19 (0.74–6.50)

0.16

2.63 (0.80–8.61)

0.11

Female

8 (29)

14 (47)

Reference

 

Reference

 

Race/ethnicity

      

 Non-hispanic white

10 (36)

11 (37)

Reference

   

 Non-hispanic black

11 (39)

8 (27)

1.51 (0.43–5.28)

0.52

  

 Hispanic/latino

7 (25)

9 (30)

0.86 (0.23–3.16)

0.82

  

 Asian

0 (0)

1 (3)

–

–

  

 Other/not reported

0 (0)

1 (3)

–

–

  

Age at time of infection

      

 18–54 years

7 (25)

8 (27)

Reference

   

 55–69 years

9 (32)

15 (50)

0.69 (0.19–2.54)

0.57

  

 ≥ 70 years

12 (43)

7 (23)

1.96 (0.49–7.77)

0.34

  

History of IV drug use

      

 Yes

0 (0)

3 (10)

–

–

  

 No

28 (100)

27 (90)

–

–

  

HIV diagnosis

      

 Yes

3 (11)

3 (10)

1.08 (0.20–5.86)

0.93

  

 No

25 (89)

27 (90)

Reference

   

Admission source

      

 Home

16 (57)

22 (73)

Reference

   

 NH/Rehab/LTACH

11 (39)

4 (13)

3.78 (1.02–14.06)

0.05

  

 Other hospital

1 (4)

4 (13)

0.34 (0.04–3.37)

0.36

  

Prior hospital admission (90 days)

      

 Yes

22 (79)

15 (50)

3.67 (1.16–11.60)

0.03

  

 No

6 (21)

15 (50)

Reference

   

Length of hospital stay prior to BSI

      

 CO-MRSA

17 (61)

19 (63)

Reference

   

 HO-MRSA

11 (39)

11 (37)

1.12 (0.39–3.23)

0.84

  

Frequent healthcare interaction

      

 Hemodialysis

9 (32)

4 (13)

3.00 (0.77–11.62)

0.11

  

 Infusion center

4 (14)

6 (20)

0.89 (0.21–3.72)

0.87

  

 None

15 (54)

20 (67)

Reference

   

Presence of invasive device

      

 Yes

26 (93)

18 (60)

8.67 (1.73–43.49)

0.009

9.75 (1.87–50.85)

0.007

 No

2 (7)

12 (40)

Reference

   

Invasive procedures (missing = 1)

      

 Yes

10 (36)

11 (37)

0.91 (0.31–2.67)

0.86

  

 No

18 (64)

18 (60)

Reference

   

Wound present

      

 Yes

18 (64)

12 (40)

2.70 (0.93–7.82)

0.07

  

 No

10 (36)

18 (60)

Reference

   

Charlson comorbidity index (CCI)

      

 0–3

5 (18)

7 (23)

Reference

   

 4–5

9 (32)

8 (27)

1.58 (0.35–7.00)

0.55

  

 6–8

11 (39)

8 (27)

1.93 (0.45–8.33)

0.38

  

 > 8

3 (11)

7 (23)

0.60 (0.10–3.54)

0.57

  

History of transplant

      

 Yes

4 (14)

1 (3)

4.83 (0.51–46.18)

0.17

  

 No

24 (86)

29 (97)

Reference

   

History of MRSA colonization

      

 Yes

9 (32)

5 (17)

2.37 (0.68–8.23)

0.17

  

 No

19 (68)

25 (83)

Reference

   

Presumed source of MRSA BSI

      

 Peripheral IV

1 (4)

5 (17)

0.19 (0.02–1.70)

0.14

  

 Skin and soft tissue infection

4 (14)

8 (27)

0.46 (0.12–1.74)

0.25

  

 Pneumonia

2 (7)

1 (3)

2.23 (0.19–26.06)

0.52

  

 Diabetic foot infection

1 (4)

0 (0)

–

–

  

 Vascular access

8 (29)

6 (20)

1.60 (0.48–5.38)

0.45

  

 Sacral wound

4 (14)

0 (0)

–

–

  

other/unknown

8 (29)

10 (33)

0.80 (0.26–2.45)

0.70

  
  1. See Table 1 for definitions
  2. Bold = significant at ≤ 0.05
  3. IV intravenous, NH nursing home, Rehab rehabilitation facility, LTACH long-term acute care hospital, CO community-onset, HO hospital-onset, MRSA methicillin-resistant Staphylococcus aureus, BSI bloodstream infection, HIV human immunodeficiency virus
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us